Part of our Psychedelics 2021: A Year in Review Series See the full series If public company valuations are anything to go by, it’s been a difficult year for the psychedelics sector. Many companies in the space have seen their share prices slashed, with ETFs like PSYK down over 50% since inception. But, a focus on public companies (of which there are now around fifty) and their share prices alone…


Previous articlePsychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II
Next articlePT286 – Joe Tafur, MD – Vital Psychedelic Conversations